{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "regularMarketChangePercent": 2.5392876, "regularMarketPrice": 16.96, "exchange": "AMS", "shortName": "VIVORYON THERAPEUTICS N.V.", "longName": "Vivoryon Therapeutics N.V.", "messageBoardId": "finmb_137369", "exchangeTimezoneName": "Europe/Amsterdam", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "nl_market", "marketState": "REGULAR", "esgPopulated": false, "priceEpsCurrentYear": -19.494251, "sharesOutstanding": 24105300, "bookValue": 1.1, "fiftyDayAverage": 14.7536, "fiftyDayAverageChange": 2.206399, "fiftyDayAverageChangePercent": 0.14954987, "twoHundredDayAverage": 11.3495, "twoHundredDayAverageChange": 5.6104994, "twoHundredDayAverageChangePercent": 0.49433893, "marketCap": 472597152, "forwardPE": -23.887323, "priceToBook": 15.41818, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "Vivoryon Therapeutics AG", "nameChangeDate": "2023-05-14", "averageAnalystRating": "1.7 - Buy", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1414396800000, "priceHint": 2, "regularMarketChange": 0.41999817, "regularMarketTime": 1684139956, "regularMarketDayHigh": 17.2, "regularMarketDayRange": "16.56 - 17.2", "regularMarketDayLow": 16.56, "regularMarketVolume": 24085, "regularMarketPreviousClose": 16.54, "fullExchangeName": "Amsterdam", "financialCurrency": "EUR", "regularMarketOpen": 16.56, "averageDailyVolume3Month": 81784, "averageDailyVolume10Day": 174910, "fiftyTwoWeekLowChange": 10.559999, "fiftyTwoWeekLowChangePercent": 1.6499999, "fiftyTwoWeekRange": "6.4 - 19.56", "fiftyTwoWeekHighChange": -2.6000004, "fiftyTwoWeekHighChangePercent": -0.13292436, "fiftyTwoWeekLow": 6.4, "fiftyTwoWeekHigh": 19.56, "earningsTimestamp": 1684234740, "earningsTimestampStart": 1684234740, "earningsTimestampEnd": 1684234740, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.65, "epsForward": -0.71, "epsCurrentYear": -0.87, "symbol": "VVY.AS"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Weinbergweg 22", "city": "Halle", "zip": "06120", "country": "Germany", "phone": "49 345 555 9900", "website": "https://www.vivoryon.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutics N.V. has a collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.", "fullTimeEmployees": 15, "companyOfficers": [{"maxAge": 1, "name": "Dr. Ulrich  Dauer Ph.D.", "age": 57, "title": "Chairman of the Management Board, CEO & Exec. Director", "yearBorn": 1965, "fiscalYear": 2022, "totalPay": {"raw": 373000, "fmt": "373k", "longFmt": "373,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Florian  Schmid", "age": 47, "title": "CFO, Member of Management Board & Exec. Director", "yearBorn": 1975, "fiscalYear": 2022, "totalPay": {"raw": 251000, "fmt": "251k", "longFmt": "251,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Michael  Schaeffer Ph.D.", "age": 53, "title": "Chief Bus. Officer, Member of the Management Board & Exec. Director", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": {"raw": 315000, "fmt": "315k", "longFmt": "315,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Manuela  Bader", "title": "Director of Investor Relations & Communications", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Frank T. Weber M.D.", "age": 62, "title": "Chief Medical Officer", "yearBorn": 1960, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Konrad  Glund", "age": 69, "title": "Co-Founder & Advisor", "yearBorn": 1953, "fiscalYear": 2018, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Hendrik  Liebers", "age": 51, "title": "Advisor", "yearBorn": 1971, "fiscalYear": 2018, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}